Bruce Booth is a partner and focuses on the discovery and development of novel medicines and therapeutic platforms.

Bruce is chairman and was founding CEO of Kymera Therapeutics (NASDAQ: KYMR) and Nimbus Therapeutics. He also serves as chairman of Hotspot Therapeutics, Matchpoint Therapeutics, and Spolia Therapeutics, and is a board member of Lifordi Immunotherapeutics and Sionna Therapeutics (NASDAQ: SION), as well as several seed stage companies. He previously served on the boards of prior Atlas companies Avila (acquired by Celgene), Lysosomal Therapeutics (acquired by Bial), Nimbus Lakshmi (acquired by Takeda), Padlock Therapeutics (acquired by BMS), Rodin Therapeutics (acquired by Alkermes), Stromedix (acquired by Biogen), and Vigil Neuroscience (NASDAQ: VIGL; acquired by Sanofi), and a number of other ventures. Since 2011, Bruce has extensively blogged about biotech and venture capital topics at LifeSciVC.com.

Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.

During the winter Bruce volunteers as a coach with New England Disabled Sports, a charity dedicated to adaptive sports. He recently joined the board of the Appalachian Mountain Club (AMC) to support outdoor recreation and conservation. Bruce also enjoys running, skiing, hiking, golfing, and fishing. He lives in Wellesley, MA and has three wonderful kids.